Are you Dr. Alam?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 49 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
130 Waverly St
Cambridge, MA 02139Phone+1 617-444-6100
Summary
- Dr. John Alam, MD is a board certified internist in Cambridge, Massachusetts. He is currently licensed to practice medicine in Massachusetts.
Education & Training
Brigham and Women's HospitalResidency, Internal Medicine, 1986 - 1989
Northwestern University The Feinberg School of MedicineClass of 1986
Certifications & Licensure
MA State Medical License 1988 - 2025- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease Start of enrollment: 2017 Dec 29
- Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease Start of enrollment: 2019 Jul 08
- Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies Start of enrollment: 2019 Sep 30
Publications & Presentations
PubMed
- 8 citationsContinuous administration of a p38α inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery ...John Alam, Michael Krakovsky, Ursula Germann, Aharon Levy
Plos One. 2020-12-04 - 53 citationsSelective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged RatsJohn J. Alam
Journal of Alzheimer's Disease. 2015-01-01 - 25 citationsPreclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration.Ying Jiang, John J Alam, Stephen N Gomperts, Paul Maruff, Afina W Lemstra
Nature Communications. 2022-09-21
Press Mentions
• News - Full StoryApril 1st, 2023- National Institute on Aging (NIA) Awards $21M Grant to Support Key Phase 2b Study of EIP Pharma's Neflamapimod in Dementia with Lewy BodiesJanuary 18th, 2023
- Continuous Administration of a p38α Inhibitor During the Subacute Phase After Transient Ischemia-Induced Stroke in the Rat Promotes Dose-Dependent Functional Recovery Accompanied by Increase in Brain BDNF Protein LevelDecember 4th, 2020
- Join now to see all
